Vandetanib plus Docetaxel versus Docetaxel for Advanced Non-Small Cell Lung Cancer: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Mancai ¹ ,  YANG Junlan ² , GAO Tianming ¹

1. The Second Clinical Medical College of Lanzhou University, Lanzhou 730000, China;2. The First Hospital of People’s Liberation Army, Lanzhou 730000, China;

Corresponding author：

YANG Junlan, Email: yangjl9999@126.com

Keywords：

Vandetanib; Docetaxel; Non-small cell lung Cancer; Meta-analysis

DOI：

10.7507/1672-2531.20110194

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To systematically evaluate the efficiency and safety of Vandetanib plus Docetaxel versus Docetaxel alone for advanced non-small cell lung cancer (NSCLC).
Methods 　The randomized controlled trials (RCTs) of Vandetanib plus Docetaxel versus Docetaxel for NSCLC published before October 26, 2010 were searched in EMbase, The Cochrane Library, PubMed, Wanfang database, VIP Database, China National Knowledge Infrastructure(CNKI), and China biological medical literature database. The methodological quality of the included studies was evaluated according to the Cochrane assessment handbook 5.0.2, and the meta-analysis was conducted by using RevMan 5.0 software.
Results 　A total of 3 RCTs involving 1 626 patients were included. The meta-analysis showed that there were positive effects between the Vandetanib group and the control group in the overall response rate (OR=1.81, 95%CI 1.37 to 2.38, P lt;0.000 1), disease control rate and 1-year survival rate; and all studies showed that Vandetanib could significantly lengthen the progression-free survival.
Conclusion 　The Vandetanib group is superior to the control group for its better effectiveness and fewer adverse effects, and it is worth referring and applying in clinic.

Citation： WANG Mancai,YANG Junlan,GAO Tianming. Vandetanib plus Docetaxel versus Docetaxel for Advanced Non-Small Cell Lung Cancer: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2011, 11(10): 1151-1155. doi: 10.7507/1672-2531.20110194 Copy

1.	2 Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med , 2004, 25(1): 3-10.
2.	刘夏, 马力, 杨克虎, 等. 长春瑞滨联合奥沙利铂对比长春瑞滨联合顺铂治疗中晚期非小细胞肺癌的系统评价. 中国癌症杂志, 2010, 13(2): 112-117.
3.	Socinski MA, Morris DE, Masters GA, et al . Chemotherapeutic management of stage IV non-small cell lung cancer. Chest , 2003, 123(1): 226S-243S.
4.	徐兵河. 多烯紫杉醇. 见: 孙燕, 主编. 临床肿瘤内科手册. 第4版. 北京: 人民卫生出版社, 2003. 571-576.
5.	Herbst RS, Sun Y, Eberhardt WE, et al . Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol , 2010, 11(7): 619-626.
6.	Heymach JV, Johnson BE, Prager D, et al . Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer. Journal of clinical oncology , 2007, 25(27): 4270-4277.
7.	Heymach JV, Paz-Ares L, De Braud, et al . Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. J Clin Oncol , 2008, 28(33): 5407-5415.
8.	嘉勉. 凡德他尼和多烯紫衫醇联用有望用于治疗肺癌. 辽宁医学杂志, 2008, 22(5): 276.
9.	韩文峰, 魏素菊. 非小细胞肺癌分子靶向治疗药物研究进展. 河北医科大学学报, 2009, 30(10): 1088-1092.
10.	于春虎, 张魁灵. 晚期非小细胞肺癌的化疗新进展. 实用全科医学, 2005, 3(1): 74-75.
11.	任振义, 白春学, 金一尊, 等. 多烯紫杉醇对非小细胞肺癌的抑制作用及其机制. 中华结核和呼吸杂志, 2003, 26(2): 127.
12.	李娃莉. 多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察. 中国现代药物应用, 2010, 4(21): 165-166.
13.	王玉萍. 多西紫杉醇周疗法加卡铂治疗老年非小细胞肺癌的疗效观察. 中外医疗, 2010, 22(1): 112-113.

1. 2 Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med , 2004, 25(1): 3-10.
2. 刘夏, 马力, 杨克虎, 等. 长春瑞滨联合奥沙利铂对比长春瑞滨联合顺铂治疗中晚期非小细胞肺癌的系统评价. 中国癌症杂志, 2010, 13(2): 112-117.
3. Socinski MA, Morris DE, Masters GA, et al . Chemotherapeutic management of stage IV non-small cell lung cancer. Chest , 2003, 123(1): 226S-243S.
4. 徐兵河. 多烯紫杉醇. 见: 孙燕, 主编. 临床肿瘤内科手册. 第4版. 北京: 人民卫生出版社, 2003. 571-576.
5. Herbst RS, Sun Y, Eberhardt WE, et al . Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol , 2010, 11(7): 619-626.
6. Heymach JV, Johnson BE, Prager D, et al . Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer. Journal of clinical oncology , 2007, 25(27): 4270-4277.
7. Heymach JV, Paz-Ares L, De Braud, et al . Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. J Clin Oncol , 2008, 28(33): 5407-5415.
8. 嘉勉. 凡德他尼和多烯紫衫醇联用有望用于治疗肺癌. 辽宁医学杂志, 2008, 22(5): 276.
9. 韩文峰, 魏素菊. 非小细胞肺癌分子靶向治疗药物研究进展. 河北医科大学学报, 2009, 30(10): 1088-1092.
10. 于春虎, 张魁灵. 晚期非小细胞肺癌的化疗新进展. 实用全科医学, 2005, 3(1): 74-75.
11. 任振义, 白春学, 金一尊, 等. 多烯紫杉醇对非小细胞肺癌的抑制作用及其机制. 中华结核和呼吸杂志, 2003, 26(2): 127.
12. 李娃莉. 多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察. 中国现代药物应用, 2010, 4(21): 165-166.
13. 王玉萍. 多西紫杉醇周疗法加卡铂治疗老年非小细胞肺癌的疗效观察. 中外医疗, 2010, 22(1): 112-113.

Previous Article
Endostar plus Chemotherapy for Non Small Cell Lung Cancer: A Systematic Review
Next Article
Effects of N-acetylcystein on Patients with Stable COPD: A Meta-analysis

Chinese Journal of Evidence-Based Medicine

Vandetanib plus Docetaxel versus Docetaxel for Advanced Non-Small Cell Lung Cancer: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content